XML 33 R21.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting
6 Months Ended
Jun. 30, 2025
Segment Reporting  
Segment Reporting

14. Segment Reporting

The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company’s chief operating decision maker (“CODM”). The Company’s CODM is its Chief Executive Officer, who reviews financial information on an aggregate basis for purposes of assessing performance, making operating decisions, allocating resources and evaluating financial performance. The Company maintains 99.4% of its $12.7 million property and equipment, net within the United States.

The following table includes certain segment information for the periods presented (in thousands):

Three Months Ended June 30, 

Six Months Ended June 30, 

2025

2024

2025

2024

Grant and award revenue

$

2,169

$

-

$

2,660

$

966

Operating expenses

Research and development expenses:

AP-PA02: Non-Cystic Fibrosis Bronchiectasis

152

1,768

(288)

3,602

AP-PA02: Cystic Fibrosis

14

138

25

235

AP-SA02: Bacteremia

1,011

1,051

1,663

1,134

AP-SA02: Prosthetic Joint Infection

1

1

2

8

Expenses not allocated by projects*

592

544

1,112

1,176

Total external research and development expenses

1,770

3,502

2,514

6,155

Research and development personnel expenses

2,293

2,809

4,606

5,422

Other research and development expenses

2,331

2,164

4,703

4,914

Total research and development expenses

6,394

8,475

11,823

16,491

General and administrative expenses:

General and administrative personnel expenses

1,191

1,571

2,592

2,505

Other general and administrative expenses

1,428

1,868

3,280

4,112

Total general and administrative expenses

2,619

3,439

5,872

6,617

Total operating expenses

9,013

11,914

17,695

23,108

Operating loss

(6,844)

(11,914)

(15,035)

(22,142)

Other income (expense), net

(9,451)

20,900

(7,791)

6,107

Net income (loss)

$

(16,295)

$

8,986

$

(22,826)

$

(16,035)